Orchestra BioMed Holdings Inc Dossier
Qualitative Analysis
Business overview
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a biomedical innovation company focused on accelerating high-impact therapeutic technologies to patients through a unique, risk-reward sharing partnership business model. Rather than acting as a traditional medical device manufacturer with direct commercial sales infrastructure, Orchestra BioMed develops clinical and preclinical product candidates and partners with market-leading global medical device companies to drive global commercialization. The company's flagship product candidates are Atrioventricular Interval Modulation (AVIM) Therapy (formerly BackBeat CNT), a bioelectronic treatment designed to lower blood pressure in pacemaker-indicated patients, and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), a first-of-its-kind drug-device combination for the treatment of atherosclerotic artery disease.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Developing the BackBeat Cardiac Neuromodulation Therapy (AVIM therapy) for patients with hypertension who are indicated for a dual-chamber pacemaker.
Expected impact: Establish clinical efficacy and safety to secure FDA and global regulatory approvals for commercialization.
Conducting the U.S. pivotal trial of the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of coronary in-stent restenosis (ISR).
Expected impact: Generate clinical data required to support U.S. regulatory approval of Virtue SAB.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Medtronic holds global commercialization rights to BackBeat CNT-enabled pacing systems, while Orchestra BioMed shares in future sales revenues [1.4.1]. The partnership was expanded in mid-2025 to provide a development framework for integrating AVIM therapy into dual-chamber leadless pacemakers.
Terms: Medtronic has contributed nearly $82 million in total capital to Orchestra BioMed, including a $20 million secured subordinated promissory note issued in Q2 2026.
Provides non-dilutive funding to advance late-stage partnered cardiology programs in exchange for future royalty interests.
Terms: Ligand committed $35 million in exchange for a tiered royalty interest in future sales of AVIM Therapy and Virtue SAB, plus a $5 million equity investment. A $15 million tranche payment was received by Orchestra BioMed on May 1, 2026, bringing total capital received from Ligand to $40 million.
Replaced a prior distribution agreement, granting Terumo a right of first refusal to acquire global rights or enter a distribution arrangement for Virtue SAB in coronary artery disease.
Terms: Terumo paid a $10 million ROFR fee and invested an additional $20 million in non-voting Series A convertible preferred stock.